PDUFA VII: Human Factors Review, Finance Flexibility, REMS, And Manufacturing Get Attention
Executive Summary
User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.
You may also be interested in...
Could US FDA Move Gene Therapy Regulation To Device Center In Years To Come?
CBER Director Peter Marks said more sophisticated manufacturing expected in the next decade could lead to questions about whether gene therapies should be regulated by his center or CDRH.
How The US FDA Honed Remote Tools To Assess Facilities During COVID Inspection Hiatus
FDA officials outline the impact of using alternative tools to assess manufacturing facilities amid COVID-19 and share key experiences around these, including with remote interactive evaluations.
How The US FDA Honed Remote Tools To Assess Facilities During COVID Inspection Hiatus
FDA officials outline the impact of using alternative tools to assess manufacturing facilities amid COVID-19 and share key experiences around these, including with remote interactive evaluations.